



Epax AS
Munkedamsveien 35
NO-0250 Oslo, Norway
Tel.: +47 70 13 59 60
www.epax.com
Org.nr. NO 994 555 405

Epax continues expansion into the pharmaceutical omega-3 segment with study on AKR963 successfully achieving phase 3 study efficacy endpoints

Oslo, Norway, November 23, 2011

Epax AS, a leader in omega-3 fatty acid concentrates, provides supply solutions to companies in both pharmaceutical and nutraceutical segments. Through recent expansion and investments Epax is strongly positioned in the fast growing prescription pharmaceutical segment. AKR-963 is a prescription drug being developed for the treatment of patients with very high triglycerides ($TG \geq 500$ mg/dL) and Epax believes that the product does not infringe on any third party intellectual property rights.

AKR963 was well tolerated and met its primary efficacy endpoints as defined in the clinical trial protocol of the TRGG-963-002 study. The study's primary endpoint, based on the percent change in triglyceride (TG) levels from baseline to week 12, was non-inferiority versus one of the class-leading medications in the field of triglyceride reduction.

"The result is an important step for Epax' development in the pharmaceutical segment" says Egil Bodd MD, PhD and Chairman of the Epax Board of Directors. "Epax continues to make significant investments in both the supplement segment and the highly regulated prescription omega-3 market, which requires a fully validated cGMP supply chain. High concentration omega-3 products represent a key competency of Epax, which was further strengthened by the acquisition of the Seal Sands facility in the UK. Epax is working on expanding its partnerships with leading companies commercializing omega-3 products in the supplement and prescription markets throughout the world, says Bodd."

About Epax

Epax AS is a leader in the omega-3 fatty acid concentrate field. The company offers a wide range of omega-3 concentrates in the pharmaceutical as well as nutraceutical business-to-business segment.

The Epax AS group is headquartered in Oslo, Norway. Its principle production facility for nutraceutical ingredients in Ålesund, Norway, is GMP certified for the manufacturing of Active Pharmaceutical Ingredients (API) by the Norwegian Medicines Agency. In addition, Epax recently acquired the former Lundbeck manufacturing facility in Seal Sands, UK, to become the company's center for the manufacturing of pharmaceutical APIs. Trygg Pharma Inc., Epax's U.S. subsidiary, is developing AKR963 and other pharmaceutical products for the U.S.

For more information please contact:

Terje Bakken, President and CEO; terje.bakken@epax.com , +47 90654227